Mark Keating is the Head of the Ophthalmology Disease Area at the Novartis Institutes for BioMedical Research (NIBR).
 

Before joining NIBR, Mark was a Professor of Cell Biology and Medicine at Harvard Medical School and an Investigator of the Howard Hughes Medical Institute. He is well known for his work on the molecular genetics of cardiovascular disease, particularly cardiac arrhythmias like long QT syndrome and Williams syndrome. He and his colleagues discovered that HERG is responsible for many drug-induced arrhythmias and developed the first HERG assay, an assay widely used in drug discovery. More recently, Mark’s scientific efforts have focused on mechanisms of cardiac regeneration.
 

Mark is a graduate of Princeton University and the Johns Hopkins University School of Medicine. He completed his Internal Medicine residency at the Johns Hopkins Hospital and a fellowship in cardiology at the University of California, San Francisco (UCSF). He did post-doctoral research training at UCSF with Lewis T. Williams. Mark has published more than 150 research publications. He has been honored with many awards and distinguished lectureships and is member of the National Academy of Sciences, USA.